Literature DB >> 33005034

Neoadjuvant therapy improves pCR rate.

Peter Sidaway1.   

Abstract

Year:  2020        PMID： 33005034     DOI： 10.1038/s41571-020-00440-6

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Authors:  Elizabeth A Mittendorf; Hong Zhang; Carlos H Barrios; Shigehira Saji; Kyung Hae Jung; Roberto Hegg; Andreas Koehler; Joohyuk Sohn; Hiroji Iwata; Melinda L Telli; Cristiano Ferrario; Kevin Punie; Frédérique Penault-Llorca; Shilpen Patel; Anh Nguyen Duc; Mario Liste-Hermoso; Vidya Maiya; Luciana Molinero; Stephen Y Chui; Nadia Harbeck
Journal:  Lancet       Date:  2020-09-20       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.